ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Rapid sono-microwave synthesis of V₂O₃ NPs: structural enhancement and Bax/Bcl-2-mediated apoptosis in cancer cells, in vitro and molecular docking insights.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
V₂O₃ NPs were successfully synthesized using a sono-microwave method with NH₄VO₃ and CTAB as raw materials. The synthesized nanoparticles were characterized using XRD, FESEM, EDS, UV-Vis, and FTIR techniques, with the results confirming the formation of crystalline plate-like nanostructures with sheets ranges from 100 to 200 nm and the length of the plate is in the range of 100-500 nm. The method has apparent efficiency, simplicity, and low cost for preparing V₂O₃. Moreover, V₂O₃ NPs were displayed in a molecular docking, and the data visualized the best prediction of inhibition towards lung, breast, and colon carcinoma. The findings showed that lung cancer with ID: 2P85 evaluated a significant total binding energy of - 9.49 kcal/mol. V₂O₃ nanoparticles exhibited potent, dose-dependent cytotoxicity against A549, HT-29, and MCF-10 cancer cell lines, as confirmed by MTT assays. V₂O₃ NPs demonstrated significant anticancer activity against lung, breast, and colorectal cancer cell models after 72 h of exposure to a concentration of 40 μg/ml. The results confirmed a clear concentration-dependent cytotoxic effect, supported by a marked modulation of apoptosis-related biomarkers. V₂O₃ NPs notably increased Bax protein expression while simultaneously decreasing BCl2 levels in all treated cancer cell lines compared to untreated control samples. Consequently, the Bax/BCl2 ratio increased considerably, reaching 2.76 in HT-29 cells, 2.20 in MCF-7 cells, and 1.68 in A549 cells, a suggestion of the mitochondrial apoptotic path.
Indexed as
Identifiers
42410222What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.